|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000621 |
Purpose
To conduct feasibility studies on the use of retinoids in the treatment of emphysema. Specific objectives are to identify optimal patient populations, retinoids, doses, dosing schedules, routes of administration, and outcome measures preparatory to conducting a larger, controlled, clinical trial on the efficacy of retinoid therapy in the management of emphysema.
| Condition | Intervention | Phase |
|
Emphysema Lung Diseases Lung Diseases, Obstructive Chronic Obstructive Pulmonary Disease |
Drug: all trans retinoic acid Drug: 13 cis retinoic acid Drug: placebo |
Phase II |
| MedlinePlus related topics: | COPD (Chronic Obstructive Pulmonary Disease) Emphysema |
| Drug Information available for: | Isotretinoin Tretinoin |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Study Start Date: | September 1999 |
| Study Completion Date: | December 2004 |
| Primary Completion Date: | December 2004 (Final data collection date for primary outcome measure) |
![]() |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 45 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations
More Information
| Study ID Numbers: | 124 |
| First Received: | October 27, 1999 |
| Last Updated: | January 15, 2008 |
| ClinicalTrials.gov Identifier: | NCT00000621 |
| Health Authority: | United States: Federal Government |
|
|
|
|